NEO: Bull Flag detected on 1 Sep 2026

NEO is forming a bull flag pattern following Q2 2026 earnings that exceeded Wall Street expectations and prompted a full-year guidance raise. The structure score of 15.0/15 indicates textbook pattern geometry, with current price at $17.91 near key resistance of $16.45. Volume at 1.54M shares (86% of 20-day average) shows adequate confirmation for a breakout setup. The breakout score of 11.5/13 and volume score of 11.2/12 suggest solid pattern quality with 76.09% historical win probability. The overall score of 82.7/98 reflects a high-conviction technical setup in a bullish sector regime (0.51 score).

NEO reported Q2 2026 revenue of $202 million, up 11% year-over-year, with adjusted EBITDA surging 36% to $14 million. The Next-Generation Sequencing (NGS) segment experienced 26% revenue growth, indicating strong demand and market penetration. Five NGS products launched since 2023 have grown more than 30% and now constitute 26% of total clinical revenue. The company achieved significant margin improvement, with adjusted gross margin expanding by 260 basis points year over year. In late July 2026, NeoGenomics reported a return to profitability with net income of $2.24 million. On July 9, 2026, NeoGenomics launched FDA-Approved PTEN IHC Companion Diagnostic for Prostate Cancer. This operational momentum has driven the 71.55% three-month gain and positions the flag within an established uptrend.

A successful breakout above key resistance at $16.45 targets the measured move of $18.50 (conservative target), representing a 3.3% advance from current price of $17.91. Historical data shows 76.09% win probability for bull flags with this quality score. Volume confirmation on breakout should exceed the current 1.54M baseline to validate upside extension. The invalidation level sits at key support of $15.48, where the prior flag consolidation began—a break below this level would signal pattern failure and potential reversal to test lower support around the 180-day rounding bottom base formed in December 2025.

The sharp share price run and guidance that still points to a full year net loss keep valuation risk front and center, especially with a relatively new management team and ongoing exposure to pharma demand swings. The recent profit surprise does not remove the risk of future earnings volatility. RSI of 63.69 indicates moderate momentum without overbought extremes. Beta of 0.67 suggests lower volatility relative to broad market, reducing downside shock risk. However, the 201.52% gain versus 52-week lows and recent 71.55% three-month rally warrant vigilance for profit-taking. The stock trades within a 52-week range of $4.72–$15.57 per historical data, and current price of $17.91 approaches resistance levels that may cap near-term advances without additional catalysts.

We scan more than 6,000 NYSE and NASDAQ stocks every trading day and compare each detected pattern against a database of 370,000+ historical detections. Every setup is scored across three dimensions: Structure, Volume, and Breakout Readiness. Win probability is a calibrated estimate of how similar historical setups performed over the following 10 trading days. This is a swing trading tool built for multi-day holds. It is not built or tested for day trading.